Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679399 | 0.90 | PTPRB (0.39) | LMNAMEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL16059632 | 0.85 | LMNA (0.39) | LMNAMEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL3694833 | 0.78 | MEN1 (0.45) | MEN1KMT2AALDH1A1CCR3GAA | |
| SCHEMBL16061264 | 0.78 | MEN1 (0.37) | LMNAMEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL28950138 | 0.77 | KMT2A (0.37) | LMNAMEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL468135 | 0.76 | PTPRB (0.53) | MEN1KMT2ACCR3NPC1PTPRB | |
| SCHEMBL1287147 | 0.75 | OPRM1 (0.52) | LMNAMEN1KMT2AALDH1A1CCR3 | |
| SCHEMBL468277 | 0.75 | MMP8 (0.44) | MEN1KMT2AALDH1A1CCR3GAA | |
| SCHEMBL19837047 | 0.73 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1CCR3GAA | |
| SCHEMBL16060603 | 0.72 | MMP2 (0.40) | MEN1KMT2AALDH1A1CCR3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | LMNA 900/4885MEN1 999/4885KMT2A 3236/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | LMNA 2304/4885MEN1 4668/4885KMT2A 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.